IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer
Cancer Science · 2025
DOI: 10.1111/cas.70297 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Science, 2025. Verfasst von Morihito Okada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche, Chugai Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). We report updated efficacy and safety results from the disease‐free survival (DFS) final and overall survival (OS) second interim analyses, with ≥ 5 years of follow‐up in Japanese patients. Patients who received 1–4 21‐day chemotherapy cycles after surgery were randomized 1:1 to receive atezolizumab 1200 mg every 3 weeks (≤ 16 cycles) or BSC. Of 149 patients enrolled, 117 were randomized to the intention‐to‐treat (ITT) population (atezolizumab n = 59; BSC n = 58). At data cutoff (January 26, 2024), unstratified hazard ratios (HRs) (95% confidence interval [CI]) for DFS in the atezolizumab versus BSC arms were 0.54 (0.28–1.07) in the stage II–IIIA programmed death‐ligand 1 (PD‐L1) tumor cell (TC) ≥ 1% ( n = 74), 0.64 (0.27–1.52) in the stage II–IIIA PD‐L1 TC 1%–49% ( n = 34), 0.52 (0.17–1.54) in the stage II–IIIA PD‐L1 TC ≥ 50% ( n = 40), 0.58 (0.34–1.00) in the stage II–IIIA all‐randomized ( n = 113), and 0.57 (0.34–0.98) in the ITT populations. OS remained immature; median OS was not reached in both treatment arms for all subgroups. Grade 3/4 adverse events occurred in 15 (26.8%) and 7 patients (12.1%) in the atezolizumab and BSC arms, respectively; no deaths were reported. In this exploratory subgroup analysis, adjuvant atezolizumab demonstrated numerically improved DFS and OS versus BSC in Japanese patients and was well tolerated, similar to the global IMpower010 population. Trial Registration: ClinicalTrials.gov identifier: NCT02486718
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
- Division of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
- Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Morihito Okada, Shunichi Sugawara, Yasushi Goto, Hirotsugu Kenmotsu
Förderung
- F. Hoffmann-La Roche
- Chugai Pharmaceutical Co. Ltd
Zitieren
APA
Okada, M., Sugawara, S., Watanabe, Y., Saito, H., Chen-Yoshikawa, T. F., Goto, Y., Nishio, W., Nakagawa, S., Hayashi, M., & Kenmotsu, H. (2025). IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70297
Vancouver
Okada M, Sugawara S, Watanabe Y, Saito H, Chen-Yoshikawa TF, Goto Y, et al. IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer. Cancer Science. 2025. doi:10.1111/cas.70297
BibTeX
@article{Okada2025,
author = {Okada, Morihito and Sugawara, Shunichi and Watanabe, Yasutaka and Saito, Haruhiro and Chen-Yoshikawa, Toyofumi F and Goto, Yasushi and Nishio, Wataru and Nakagawa, Shizuka and Hayashi, Morihiko and Kenmotsu, Hirotsugu},
title = {IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70297}
}
EUVIMED